Molecular mechanisms of membrane disruption induced by early-stage aggregation of beta-amyloid peptides

β-淀粉样肽早期聚集诱导膜破坏的分子机制

基本信息

  • 批准号:
    10319959
  • 负责人:
  • 金额:
    $ 27.65万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-01-01 至 2024-12-31
  • 项目状态:
    已结题

项目摘要

Project Summary Because of the recent failures in the development of anti-amyloid therapeutic strategies for curing Alzheimer's disease (AD), it is prompt to re-evaluate the existing amyloid cascade hypothesis from all possible aspects. Among all these efforts, biophysical and structural characterizations of β-amyloid aggregates in in- vitro model systems, especially the works that involve the high-resolution solid-state nuclear magnetic resonance (ssNMR) spectroscopy, provide invaluable information from the fundamental sides. However so far, most of these high-resolution works have been focused on the atomic structures of either amyloid fibrils or non- fibrillar aggregates. Very little high-resolution studies have been performed to directly probe the cellular membrane disruption effects induced by the aggregation process of β-amyloid peptides, which are potentially associated with the neurotoxicity mechanisms of the β-amyloid aggregates. A major challenge that prevented the high-resolution studies of β-amyloid-peptide-induced membrane disruption effects in model systems was the heterogeneity, which usually involved co-existence of multiple membrane disruption pathways with mixed intermediate structures. This proposal attempts to solve this problem by generating model systems with distinct predominant membrane disruption effects. These model systems, which contain different β amyloid aggregates and phospholipid liposomes, are characterized by distinct time-dependent membrane disruption features and structurally homogeneous endpoints. Therefore, they can be studied individually in terms of their membrane disruption effects using high-resolution ssNMR approaches. The outcomes of this proposal, if successful, will provide crucial insights on the high-resolution molecular interactions between β amyloid aggregates and membranes that are responsible to the membrane disruption. These information help to explain the neuronal cellular toxicity of β-amyloid aggregates, which further contribute to the re-evaluation of amyloid cascade hypothesis.
项目摘要 由于最近开发抗淀粉样蛋白治疗策略的失败, 阿尔茨海默病(AD),这是提示重新评估现有的淀粉样蛋白级联假说,从所有可能的 方面在所有这些努力中,β-淀粉样蛋白聚集体的生物物理学和结构特征, 体外模型系统,特别是涉及高分辨率固态核磁共振的工作 核磁共振(ssNMR)光谱,提供了宝贵的信息,从基本方面。然而到目前为止, 这些高分辨率的工作大多集中在淀粉样蛋白原纤维或非淀粉样蛋白原纤维的原子结构上, 纤维状聚集体。很少有高分辨率的研究已经进行了直接探测细胞 β-淀粉样肽的聚集过程诱导的膜破裂效应,这可能是 与β-淀粉样蛋白聚集体的神经毒性机制相关。 阻碍β-淀粉样肽诱导的膜的高分辨率研究的主要挑战 模式系统的干扰效应是异质性,通常涉及多种干扰的共存 具有混合中间结构的膜破坏途径。该提案试图解决这一问题 通过生成具有不同的主导膜破坏效应的模型系统来解决问题。这些模型 含有不同β淀粉样蛋白聚集体和磷脂脂质体的系统的特征在于: 不同的时间依赖性膜破裂特征和结构均匀的终点。因此,我们认为, 可以使用高分辨率ssNMR单独研究它们的膜破坏效应 接近。 这项提案的结果如果成功,将为高分辨率 β淀粉样蛋白聚集体和膜之间的分子相互作用, 破坏这些信息有助于解释β-淀粉样蛋白聚集体的神经细胞毒性, 进一步有助于重新评估淀粉样蛋白级联假说。

项目成果

期刊论文数量(14)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Application of DNP-enhanced solid-state NMR to studies of amyloid-β peptide interaction with lipid membranes.
  • DOI:
    10.1016/j.chemphyslip.2021.105071
  • 发表时间:
    2021-05
  • 期刊:
  • 影响因子:
    3.4
  • 作者:
    Deo T;Cheng Q;Paul S;Qiang W;Potapov A
  • 通讯作者:
    Potapov A
N-Terminal Modified Aβ Variants Enable Modulations to the Structures and Cytotoxicity Levels of Wild-Type Aβ Fibrils through Cross-Seeding.
  • DOI:
    10.1021/acschemneuro.0c00316
  • 发表时间:
    2020-07-15
  • 期刊:
  • 影响因子:
    5
  • 作者:
    Hu ZW;Au DF;Cruceta L;Vugmeyster L;Qiang W
  • 通讯作者:
    Qiang W
Early stage β-amyloid-membrane interactions modulate lipid dynamics and influence structural interfaces and fibrillation.
  • DOI:
    10.1016/j.jbc.2022.102491
  • 发表时间:
    2022-10
  • 期刊:
  • 影响因子:
    4.8
  • 作者:
    Kenyaga, June M.;Cheng, Qinghui;Qiang, Wei
  • 通讯作者:
    Qiang, Wei
Model Phospholipid Liposomes to Study the β-Amyloid-Peptide-Induced Membrane Disruption.
Time-Dependent Lipid Dynamics, Organization and Peptide-Lipid Interaction in Phospholipid Bilayers with Incorporated β-Amyloid Oligomers.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Wei Qiang其他文献

Wei Qiang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似国自然基金

新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
  • 批准号:
    81000622
  • 批准年份:
    2010
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
  • 批准号:
    31060293
  • 批准年份:
    2010
  • 资助金额:
    26.0 万元
  • 项目类别:
    地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
  • 批准号:
    30960334
  • 批准年份:
    2009
  • 资助金额:
    22.0 万元
  • 项目类别:
    地区科学基金项目

相似海外基金

Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
  • 批准号:
    10657993
  • 财政年份:
    2023
  • 资助金额:
    $ 27.65万
  • 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
  • 批准号:
    10381163
  • 财政年份:
    2022
  • 资助金额:
    $ 27.65万
  • 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
  • 批准号:
    10531959
  • 财政年份:
    2022
  • 资助金额:
    $ 27.65万
  • 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
  • 批准号:
    10700991
  • 财政年份:
    2022
  • 资助金额:
    $ 27.65万
  • 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
  • 批准号:
    10518582
  • 财政年份:
    2022
  • 资助金额:
    $ 27.65万
  • 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
  • 批准号:
    10672973
  • 财政年份:
    2022
  • 资助金额:
    $ 27.65万
  • 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
  • 批准号:
    10585925
  • 财政年份:
    2022
  • 资助金额:
    $ 27.65万
  • 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
  • 批准号:
    10180000
  • 财政年份:
    2021
  • 资助金额:
    $ 27.65万
  • 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
  • 批准号:
    10049426
  • 财政年份:
    2021
  • 资助金额:
    $ 27.65万
  • 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
  • 批准号:
    10295809
  • 财政年份:
    2021
  • 资助金额:
    $ 27.65万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了